
AbbVie posts strong Q4 results
pharmafile | February 1, 2016 | News story | Sales and Marketing |Â Â AbbVie, Humira, Viekira PakÂ
AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing to adjusted global revenues of $6.4 billion for the quarter and $22.82 billion for the whole of 2015- up 22.1% on the previous year
Hepatitis C regimen Viekira Pak also contributed $554 million in the fourth quarter, and AbbVie pointed to strong operational growth from Duodopa, Creon and Lupron. The Illinois, US-based company also found significant efficiencies in selling, general and administration costs- reducing its bill 48% to $1.74 billion from $3.34 billion.
Adjusted earnings per share for 2015 were $4.29, up 29% from the $3.32 of 2014- a year in which profits were hit by administration costs from the aborted Shire takeover.
The strong results led AbbVie to confidently predict it would be amongst the industry leaders for growth in 2016.
“AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projections for the year,” says Richard Gonzalez, chairman and chief executive officer, AbbVie. “We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance.”
Joel Levy
Related Content

Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …

Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …






